Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma

Inclusion Criteria

• •The patient must be enrolled on ACCRN07 and/or APEC14B1 and registered with COG by a North American member institution
• •The patient must have a diagnosis of embryonal rhabdomyosarcoma or alveolar rhabdomyosarcoma
• •The patient must be diagnosed with rhabdomyosarcoma between January 1, 2012 and November 30, 2019
• •Concomitant treatment on a therapeutic trial is not required
• •The patient must have at least one biological parent alive and willing to participate
• •All questionnaire respondents must understand English or Spanish
• •All patients and/or their parents or legal guardians must sign a written informed consent
• •All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met